"Current platinum-based anti-cancer drugs, such as cisplatin, are well established in the successful treatment of various forms of cancer, however, the use of these drugs is significantly limited by associated side effects and drug resistance. Ruthenium-based alternatives, some of which are in clinical testing, have shown considerable promise, exhibiting low general toxicity alongside selectivity ...